Fundraising FoxSeroba Life Sciences — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach.
BiotechDeep TechHealthtech
Tjeerd Barf(Co-founder & CEO)inArwin Ridder(Co-founder & COO)inAd IJzerman(Co-founder & SAB Chair)inJason(Chief Scientific Officer)in
Co-investorsBioGeneration VenturesThuja CapitalBGV
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.
BiotechDigital HealthHealthtechMedical DevicesMunich, DE
Rafiq Hasan(CEO and Managing Director)inMuhammad Ali Memon(Chief Medical Officer)in
Co-investorsBioGeneration VenturesCambridge Innovation CapitalGimvHadean VenturesBGVForbion+2 more
Deciphex develops AI-powered platforms to enhance pathology efficiency, including digital image analysis, clinical trial support, and a global network of subspecialty pathologists.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Co-investorsAct Venture CapitalACT Venture CapitalClaret Capital PartnersMolten Ventures
Shorla Oncology develops pharmaceutical products to address unmet needs in oncology.
BiotechHealthtechMedical DevicesDublin, IE
Sharon Cunningham(CEO & Co-Founder)inOrlaith Ryan(CTO & Co-Founder)in
Co-investorsKurma PartnersEnterprise Ireland
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.